Author(s): McCarthy E.M.; Parker B.; Bruce I.N.; Sutton E.; Nesbit S.; Jayne D.; Griffiths B.; Isenberg D.A.; Rahman A.; Gordon C.; D'Cruz D.P.; Rhodes B.; Lanyon P.; Vital E.M.; Yee C.-S.; Edwards C.J.; Teh L.-S.; Akil M.; McHugh N.J.; Zoma A.

Source: Rheumatology (United Kingdom); Jun 2017; vol. 56 (no. 6); p. 1049

Publication Date: Jun 2017

Publication Type(s): Erratum

Abstract:The title of the above paper has been adapted after publication ahead of print. The original title of The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence has been adapted to The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.Copyright © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
​
Database: EMBASE

​Author(s): McCarthy E.M.; Parker B.; Bruce I.N.; Sutton E.; Nesbit S.; Jayne D.; Griffiths B.; Isenberg D.A.; Rahman A.; Gordon C.; D'Cruz D.P.; Rhodes B.; Lanyon P.; Vital E.M.; Yee C.-S.; Edwards C.J.; Teh L.-S.; Akil M.; McHugh N.J.; Zoma A.

Source: Rheumatology (United Kingdom); Jun 2017; vol. 56 (no. 6); p. 1041-1043

Publication Date: Jun 2017

Publication Type(s): Letter
​
Database: EMBASE

Source: Arthritis Care and Research; Oct 2016; vol. 68 (no. 10); p. 1505-1513

Publication Type(s): Journal: Article

Author(s): McElhone K.; Teh L.-S.; Abbott J.; Sutton C.; Mullen M.; Lanyon P.; Rahman A.; Yee C.-S.; Akil M.; Bruce I.N.; Ahmad Y.; Gordon C.

Abstract:Objective: As a health-related quality of life (HRQOL) measure, the LupusQoL is a reliable and valid measure for adults with systemic lupus erythematosus (SLE). This study evaluates the responsiveness and minimal important differences (MIDs) for the 8 LupusQoL domains. Methods: Patients experiencing a flare were recruited from 9 UK centers. At each of the 10 monthly visits, HRQOL (LupusQoL, Short Form 36 health survey [SF-36]), global rating of change (GRC), and disease activity using the British Isles Lupus Assessment Group 2004 index were assessed.

The responsiveness of the LupusQoL and the SF-36 was evaluated primarily when patients reported an improvement or deterioration on the GRC scale and additionally with changes in physician-reported disease activity. MIDs were estimated as mean changes when minimal change was reported on the GRC scale. Results: A total of 101 patients were recruited. For all LupusQoL domains, mean HRQOL worsened when patients reported deterioration and improved when patients reported an improvement in GRC; SF-36 domains showed comparable responsiveness.

​Improvement in some domains of the LupusQoL/SF-36 was observed with a decrease in disease activity, but when disease activity worsened, there was no significant change. LupusQoL MID estimates for deterioration ranged from -2.4 to -8.7, and for improvement from 3.5 to 7.3; for the SF-36, the same MID estimates were -2.0 to -11.1 and 2.8 to 10.9, respectively. Conclusion: All LupusQoL domains are sensitive to change with patient-reported deterioration or improvement in health status. For disease activity, some LupusQoL domains showed responsiveness when there was improvement but none for deterioration. LupusQoL items were derived from SLE patients and provide the advantage of disease-specific domains, important to the patients, not captured by the SF-36.